JB/CALL/GILEAD SCIENCES/85/0.05/20.06.25

JB/CALL/GILEAD SCIENCES/85/0.05/20.06.25 Stock

GILUJB

CH1317199334

Market Closed - Swiss Exchange 11:20:00 2024-06-28 am EDT
0.12 ^CHF	-7.69%

Current month	+100.00%
1 month	+71.43%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart JB/CALL/GILEAD SCIENCES/85/0.05/20.06.25

Latest news about GILEAD SCIENCES, INC.

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	Jun. 26	CI
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117	Jun. 26	MT
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	Jun. 25	CI
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	Jun. 24	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-28	0.12	-7.69%
24-06-26	0.13	-13.33%
24-06-25	0.15	-6.25%
24-06-24	0.16	+6.67%
24-06-21	0.15	+50.00%

Delayed Quote Swiss Exchange

Last update June 28, 2024 at 11:20 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Bank Julius Bär
	GILUJB
ISIN	CH1317199334
Date issued	2024-01-12
Strike	85 $
Maturity	2025-06-20 (357 Days)
Parity	20 : 1
Emission price	0.48 CHF
Emission volume	N/A
Settlement	cash
Currency	CHF

Technical Indicators

Highest since issue	0.52 CHF
Lowest since issue	0.06 CHF
Spread	0.01 CHF
Spread %	8.33%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Gilead Sciences, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

68.61 USD

Average target price

82.97 USD

Spread / Average Target

+20.93%

Consensus